Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?

Mahtani RL, Vogel CL.

J Clin Oncol. 2008 Dec 10;26(35):5823-4. doi: 10.1200/JCO.2008.19.8226. Epub 2008 Nov 10. No abstract available.

PMID:
19001341
2.

Herceptin (trastuzumab): adjuvant and neoadjuvant trials.

Yaal-Hahoshen N, Safra T.

Isr Med Assoc J. 2006 Jun;8(6):416-21. Review. No abstract available.

3.

Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer.

Kurosumi M.

Breast Cancer. 2009;16(4):283. doi: 10.1007/s12282-009-0168-y. No abstract available.

PMID:
19756922
4.

Trastuzumab in breast cancer.

Banna GL, Santoro A.

N Engl J Med. 2006 Feb 9;354(6):640-4; author reply 640-4. No abstract available.

PMID:
16470951
5.

Isolated tumor cells in breast cancer.

Sonke GS, Linn SC.

N Engl J Med. 2009 Nov 12;361(20):1995; author reply 1995-6. No abstract available.

PMID:
19911470
6.

Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.

Dent R, Clemons M.

Cancer Treat Rev. 2006 Apr;32(2):144-8. Epub 2006 Mar 6. No abstract available.

PMID:
16517084
7.

[Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].

Láng I, Hitre E.

Magy Onkol. 2006;50(4):293-302. Epub 2007 Jan 10. Hungarian.

8.

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.

Burstein HJ, Winer EP.

J Clin Oncol. 2009 Dec 1;27(34):5671-3. doi: 10.1200/JCO.2009.24.2222. Epub 2009 Nov 2. No abstract available.

PMID:
19884535
9.

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.

J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25.

PMID:
21788566
10.

Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.

Ladoire S, Arnould L, Mignot G, Coudert B, Rébé C, Chalmin F, Vincent J, Bruchard M, Chauffert B, Martin F, Fumoleau P, Ghiringhelli F.

Breast Cancer Res Treat. 2011 Jan;125(1):65-72. doi: 10.1007/s10549-010-0831-1. Epub 2010 Mar 13.

11.

[Herceptin (trastuzumab)].

Yamashiro H, Toi M.

Gan To Kagaku Ryoho. 2007 Aug;34(8):1173-6. Review. Japanese.

PMID:
17687197
12.

Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):39. Review.

PMID:
23444499
13.

Pathologic tumor response of invasive lobular carcinoma to neo-adjuvant chemotherapy.

Joh JE, Esposito NN, Kiluk JV, Laronga C, Khakpour N, Soliman H, Catherine Lee M.

Breast J. 2012 Nov-Dec;18(6):569-74. doi: 10.1111/tbj.12006. Epub 2012 Oct 4.

PMID:
23034096
14.
15.

[Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].

Mallmann P.

Internist (Berl). 2006 Nov;47(11):1183-5. German. No abstract available.

PMID:
17048017
16.

Microinvasive lobular carcinoma of the breast.

Howat AJ, Armour A, Ellis IO.

Histopathology. 2000 Nov;37(5):477-8. No abstract available.

PMID:
11119139
17.

Trastuzumab--mechanism of action and use in clinical practice.

Hudis CA.

N Engl J Med. 2007 Jul 5;357(1):39-51. Review. No abstract available.

PMID:
17611206
18.

Trastuzumab administration associated with change in HER2 status.

Dawood S, Resetkova E, Gonzalez-Angulo AM.

Clin Breast Cancer. 2008 Aug;8(4):366-9. doi: 10.3816/CBC.2008.n.044.

PMID:
18757266
19.

Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.

Altundag K, Baptista MZ.

Breast J. 2006 Sep-Oct;12(5):497-8. No abstract available.

PMID:
16958977
20.

[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Chinese.

PMID:
21029696

Supplemental Content

Support Center